Artikel ; Online: Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab.
Acta bio-medica : Atenei Parmensis
2019 Band 90, Heft 4, Seite(n) 468–474
Abstract: Background: In clinical trials with immunotherapy, histological features such as tumor-infiltrating lymphocytes (TILs) are investigated as potential predictive biomarkers, with the limit of an outdated parameter for a typically dynamic element.: ... ...
Abstract | Background: In clinical trials with immunotherapy, histological features such as tumor-infiltrating lymphocytes (TILs) are investigated as potential predictive biomarkers, with the limit of an outdated parameter for a typically dynamic element. Methods: This explorative study compared, in metastatic renal cell carcinoma (mRCC) patients, basal pathological data about TILs on diagnostic histological specimens with circulating lymphocyte subpopulations measured before and during therapy with nivolumab. Results: Of 11 mRCC patients, 5 had low presence of TILs (L-TILs), 3 moderate amount (M-TILs) and 3 high number (H-TILs). Overall, 8 patients had low intratumoral pathological CD4+/CD8+ ratio (LIPR) ≤1 and 3 cases high intratumoral pathological ratio (HIPR) ≥2. Of 8 patients with LIPR, only 2 matched with low circulating CD4+/CD8+ ratio (LCR) ≤1; 5 had high circulating ratio (HCR) ≥2. All 3 cases with HIPR (≥2) conversely had LCR (≤1). Circulating CD4+/CD8+ ratio remained unchanged during therapy (mean -0.12 in 8 weeks). The respective percentage values of CD4+ and CD8+ circulating T cells also remained stable (variation 0%); the absolute value of CD4+ was more likely to increase (mean +46.3/mm3); the level of CD8+ tended to slightly decrease (mean -6.5/mm3). No correlation of lymphocyte subpopulations with treatment outcome was found. Of note, we did not evidence correspondence between histopathological and circulating findings in terms of T-lymphocyte subpopulations, also suggesting the inconsistency of circulating data in terms of relative variations. Conclusions: Considering the likely high dynamism of TILs, rebiopsy before therapy might be proposed to assess the utility of TILs characterization for predictive purpose. (www.actabiomedica.it). |
---|---|
Mesh-Begriff(e) | Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/therapeutic use ; Carcinoma, Renal Cell/blood ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/secondary ; Correlation of Data ; Female ; Humans ; Kidney Neoplasms/blood ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Lymphocyte Subsets ; Lymphocytes, Tumor-Infiltrating ; Male ; Middle Aged ; Neoplasm Staging ; Nivolumab/therapeutic use |
Chemische Substanzen | Antineoplastic Agents, Immunological ; Nivolumab (31YO63LBSN) |
Sprache | Englisch |
Erscheinungsdatum | 2019-12-23 |
Erscheinungsland | Italy |
Dokumenttyp | Journal Article |
ZDB-ID | 2114240-3 |
ISSN | 2531-6745 ; 0392-4203 |
ISSN (online) | 2531-6745 |
ISSN | 0392-4203 |
DOI | 10.23750/abm.v90i4.7057 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.B 925: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.